{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:45:19Z","timestamp":1782758719959,"version":"3.54.5"},"reference-count":309,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024-MS-063"],"award-info":[{"award-number":["2024-MS-063"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701570"],"award-info":[{"award-number":["81701570"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijbiomac.2025.139829","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:06:08Z","timestamp":1736769968000},"page":"139829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers"],"prefix":"10.1016","volume":"297","author":[{"given":"Hongli","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianyue","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0005","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.stem.2021.04.005","article-title":"Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids","volume":"28","author":"Marsee","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.139829_bb0010","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41568-023-00602-5","article-title":"Cancers make their own luck: theories of cancer origins","volume":"23","author":"Jassim","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0015","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0020","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0035","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates ofincidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10360","key":"10.1016\/j.ijbiomac.2025.139829_bb0045","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma \u2014 evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0060","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/annonc\/mdy510","article-title":"Correction to: \u201cHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u201d","volume":"30","author":"Vogel","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0065","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"102","key":"10.1016\/j.ijbiomac.2025.139829_bb0070","article-title":"Curcumae rhizoma and its major constituents against hepatobiliary disease: Pharmacotherapeutic properties and potential clinical applications","volume":"20","author":"Gao","year":"2022","journal-title":"Phytomedicine"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0075","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1039\/D0FO03052J","article-title":"Essential oil from the raw and vinegar-processed Rhizoma Curcumae ameliorate CCl4-induced liver fibrosis: integrating network pharmacology and molecular mechanism evaluation","volume":"12","author":"Chen","year":"2021","journal-title":"Food. Funct."},{"issue":"Pt 2","key":"10.1016\/j.ijbiomac.2025.139829_bb0080","article-title":"The raw and vinegar-processed Curcuma phaeocaulis Val. ameliorate TAA-induced zebrafish liver injury by inhibiting TLR4\/MyD88\/NF-\u03baB signaling pathway","volume":"319","author":"Gao","year":"2024","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1142\/S0192415X24500162","article-title":"Components from Curcuma longa (Turmeric) against hepatobiliary diseases based on gut\u2013liver axis: Pharmacotherapeutic properties and potential clinical applications","volume":"52","author":"Gao","year":"2024","journal-title":"Am. J. Chin. Med."},{"issue":"135","key":"10.1016\/j.ijbiomac.2025.139829_bb0090","article-title":"The processing mechanism of vinegar-processed Curcumae Rhizome enhances anti hepatic fibrotic effects through regulation of PI3K\/Akt\/mTOR signaling pathway","volume":"12","author":"Li","year":"2024","journal-title":"Phytomedicine"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0095","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0105","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0110","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0115","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.139829_bb0125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"6382","key":"10.1016\/j.ijbiomac.2025.139829_bb0130","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0150","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0155","first-page":"100","article-title":"Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy","volume":"2","author":"Kravets","year":"2017","journal-title":"J. Immunol. Res. Ther."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.139829_bb0160","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: a quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark. Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0170","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0180","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/biomedicines10071493","article-title":"Alternative CAR therapies: recent approaches in engineering chimeric antigen receptor immune cells to combat cancer","volume":"10","author":"Moreno","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0185","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3\u20134","key":"10.1016\/j.ijbiomac.2025.139829_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18632\/oncoscience.406","article-title":"Programming a serial killer: CAR T cells form non-classical immune synapses","volume":"5","author":"Davenport","year":"2018","journal-title":"Oncoscience"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0195","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0200","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.cdd.4402244","article-title":"Mechanisms of granule-dependent killing","volume":"15","author":"Cullen","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0205","doi-asserted-by":"crossref","first-page":"e36688","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0210","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1517\/14728222.9.5.1031","article-title":"Targeting the Fas\/Fas ligand pathway in cancer","volume":"9","author":"O\u2019Brien","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Pathol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0220","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.trecan.2018.01.007","article-title":"Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma","volume":"4","author":"H\u00f8gdall","year":"2018","journal-title":"Trends Cancer"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0225","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer \u2014 clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0230","doi-asserted-by":"crossref","first-page":"188356","DOI":"10.1016\/j.bbcan.2020.188356","article-title":"Fibrosis and cancer: a strained relationship","volume":"1873","author":"Piersma","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0235","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/cancers16081470","article-title":"Targeted therapy for highly desmoplastic and immunosuppressive tumor microenvironment of pancreatic ductal adenocarcinoma","volume":"16","author":"Olaoba","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0240","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1038\/s41467-023-40727-7","article-title":"Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"issue":"Suppl. 1","key":"10.1016\/j.ijbiomac.2025.139829_bb0245","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hep.31410","article-title":"The tumor microenvironment in cholangiocarcinoma progression","volume":"73","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0250","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","article-title":"Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer","volume":"13","author":"Falcomat\u00e0","year":"2023","journal-title":"Cancer Discov."},{"issue":"20","key":"10.1016\/j.ijbiomac.2025.139829_bb0255","doi-asserted-by":"crossref","first-page":"e163022","DOI":"10.1172\/jci.insight.163022","article-title":"Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer","volume":"8","author":"Kitamura","year":"2023","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0260","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3892\/mco.2017.1415","article-title":"Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients","volume":"7","author":"Chen","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0265","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fphar.2017.00126","article-title":"Dual functional capability of dendritic cells\u2014cytokine-induced killer cells in improving side effects of colorectal cancer therapy","volume":"8","author":"Mosi\u0144ska","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0270","doi-asserted-by":"crossref","first-page":"655697","DOI":"10.3389\/fimmu.2021.655697","article-title":"Hepatocellular carcinoma immune landscape and the potential of immunotherapies","volume":"12","author":"Giraud","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0275","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.3390\/ijms23073778","article-title":"Tumor microenvironment of hepatocellular carcinoma: challenges and opportunities for new treatment options","volume":"23","author":"Sas","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0280","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/hep.31792","article-title":"Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression","volume":"73","author":"Song","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0285","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2022.02.032","article-title":"T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma","volume":"77","author":"Barsch","year":"2022","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0290","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.3390\/ijms22115801","article-title":"Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review","volume":"22","author":"Oura","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. S1","key":"10.1016\/j.ijbiomac.2025.139829_bb0295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0300","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0305","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1084\/jem.20182395","article-title":"Development of immune checkpoint therapy for cancer","volume":"216","author":"Fritz","year":"2019","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0310","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0315","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.26694","article-title":"Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma","volume":"59","author":"Han","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0320","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.139829_bb0325","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/ijms21124414","article-title":"Immuno-metabolism and microenvironment in cancer: key players for immunotherapy","volume":"21","author":"Giannone","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0330","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/annonc\/mdz285","article-title":"Development of adaptive immune effector therapies in solid tumors","volume":"30","author":"Comoli","year":"2019","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0335","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.drudis.2018.01.024","article-title":"From clinical proof-of-concept to commercialization of CAR T cells","volume":"23","author":"Calmels","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0340","doi-asserted-by":"crossref","first-page":"1673129","DOI":"10.1080\/2162402X.2019.1673129","article-title":"The promise of adoptive cellular immunotherapies in hepatocellular carcinoma","volume":"9","author":"Hendrickson","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0345","doi-asserted-by":"crossref","first-page":"1411393","DOI":"10.3389\/fimmu.2024.1411393","article-title":"Engineering strategies to safely drive CAR T-cells into the future","volume":"15","author":"Rossi","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0350","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.5114\/aoms.2019.84888","article-title":"Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors","volume":"17","author":"Zhang","year":"2021","journal-title":"Arch. Med. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0355","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/cancers11030316","article-title":"Tumor neovascularization and developments in therapeutics","volume":"11","author":"Katayama","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0360","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0365","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.139829_bb0370","doi-asserted-by":"crossref","first-page":"e23670","DOI":"10.1096\/fj.202400286R","article-title":"Impact of heparanase-2 (Hpa2) on cancer and inflammation: advances and paradigms","volume":"38","author":"Vlodavsky","year":"2024","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0375","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0380","doi-asserted-by":"crossref","first-page":"648187","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast activation protein-alpha as a target in the bench-to-bedside diagnosis and treatment of tumors: a narrative review","volume":"11","author":"Xin","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0385","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3390\/ijms20071723","article-title":"The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma","volume":"20","author":"Baglieri","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0390","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0395","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0400","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","article-title":"FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0405","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0410","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T-cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0415","doi-asserted-by":"crossref","first-page":"e10515","DOI":"10.15252\/emmm.201910515","article-title":"Targeting TGF\u03b2r2- mutant tumors exposes vulnerabilities to stromal TGF\u03b2 blockade in pancreatic cancer","volume":"11","author":"Huang","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0420","doi-asserted-by":"crossref","first-page":"e006130","DOI":"10.1136\/jitc-2022-006130","article-title":"Synergistic therapeutic combination with a CAF inhibitor enhances CARNK-mediated cytotoxicity via reduction of CAF-released IL-6","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0425","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0430","doi-asserted-by":"crossref","first-page":"e005891","DOI":"10.1136\/jitc-2022-005891","article-title":"Novel banana lectin CAR-T cells to target pancreatic tumors and tumor associated stroma","volume":"11","author":"McKenna","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0435","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/cancers9070092","article-title":"Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy","volume":"9","author":"Sridhar","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.139829_bb0440","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0445","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0450","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jcyt.2023.10.007","article-title":"Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study","volume":"26","author":"Qian","year":"2024","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0455","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.hbpd.2018.05.005","article-title":"Chimeric antigen receptor-engineered T-cell therapy for liver cancer","volume":"17","author":"Chen","year":"2018","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0460","series-title":"HITM-SURE: Phase Ib CAR-T Hepatic Artery Infusion Trial for Stage IV Adenocarcinoma Using Pressure-enabled Drug Delivery Technology","author":"Katz","year":"2018"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0465","doi-asserted-by":"crossref","first-page":"e001097","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0470","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0475","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.139829_bb0480","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0485","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1073\/pnas.1814642116","article-title":"IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses","volume":"116","author":"Santana Carrero","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.139829_bb0490","doi-asserted-by":"crossref","first-page":"e003441","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0495","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0500","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0505","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1158\/2326-6066.CIR-22-0115","article-title":"Secreted Fas decoys enhance the antitumor activity of engineered and bystander T cells in Fas ligand-expressing solid tumors","volume":"10","author":"Bajgain","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0510","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0515","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/s41590-021-00987-1","article-title":"TCF-1 controls Treg cell functions that regulate inflammation, CD8+ T cell cytotoxicity and severity of colon cancer","volume":"22","author":"Osman","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0520","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3389\/fimmu.2019.01691","article-title":"An IL-4\/21 inverted cytokine receptor improving CAR-T cell potency in immunosuppressive solid-tumor microenvironment","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0525","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0530","doi-asserted-by":"crossref","first-page":"958960","DOI":"10.3389\/fimmu.2022.958960","article-title":"Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0535","doi-asserted-by":"crossref","first-page":"1782728","DOI":"10.1155\/2021\/1782728","article-title":"Combination of AAV-CCL19 and GPC3 CAR-T cells in the treatment of hepatocellular carcinoma","volume":"2021","author":"Meng","year":"2021","journal-title":"J. Immunol. Res."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0540","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0545","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0550","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","article-title":"GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy","volume":"39","author":"Lu","year":"2023","journal-title":"Cell Biol. Toxicol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0555","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14771","article-title":"Co-expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro","volume":"41","author":"Xiong","year":"2021","journal-title":"Liver Int."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0560","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0565","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.surg.2017.10.056","article-title":"Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro","volume":"163","author":"Batchu","year":"2018","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0570","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cac2.12452","article-title":"Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins","volume":"43","author":"Qiao","year":"2023","journal-title":"Cancer Commun. (Lond.)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0575","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1800033","article-title":"Armored inducible expression of IL-12 enhances antitumor activity of Glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma","volume":"203","author":"Liu","year":"2019","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.139829_bb0580","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1002\/cam4.2361","article-title":"Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12","volume":"8","author":"Chi","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0585","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fimmu.2019.00333","article-title":"Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy","volume":"10","author":"Vilgelm","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0590","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0595","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2 modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0600","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-024-03648-y","article-title":"Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma","volume":"73","author":"Dai","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0605","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-kB\/SDF-1a axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0610","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","article-title":"T cells armed with the C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours","volume":"5","author":"Lesch","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.139829_bb0615","doi-asserted-by":"crossref","first-page":"eabi5781","DOI":"10.1126\/sciadv.abi5781","article-title":"Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors","volume":"7","author":"Cadilha","year":"2021","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0620","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0625","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ijbiomac.2025.139829_bb0630","doi-asserted-by":"crossref","first-page":"eaaz3223","DOI":"10.1126\/sciadv.aaz3223","article-title":"Chimeric antigen receptor signaling: functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0635","doi-asserted-by":"crossref","first-page":"855871","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0640","doi-asserted-by":"crossref","first-page":"a002436","DOI":"10.1101\/cshperspect.a002436","article-title":"An enigmatic tail of CD28 signaling","volume":"2","author":"Boomer","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0645","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neo.2021.12.005","article-title":"Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models","volume":"24","author":"Lee","year":"2022","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0650","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/cancers12092567","article-title":"The landscape of CAR-T cell clinical trials against solid tumors\u2014a comprehensive overview","volume":"12","author":"Schaft","year":"2020","journal-title":"Cancers"},{"issue":"625","key":"10.1016\/j.ijbiomac.2025.139829_bb0655","doi-asserted-by":"crossref","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"41BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci. Signal."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0660","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0665","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/ AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0670","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41423-018-0183-z","article-title":"Transmembrane domain-mediated Lck association underlies by-stander and costimulatory ICOS signaling","volume":"17","author":"Wan","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0675","doi-asserted-by":"crossref","first-page":"109333","DOI":"10.1016\/j.biopha.2019.109333","article-title":"Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL41BB promote CAR-T proliferation and tumor rejection","volume":"118","author":"Hu","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"578","key":"10.1016\/j.ijbiomac.2025.139829_bb0680","doi-asserted-by":"crossref","first-page":"eaba7308","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0685","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0690","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.ymthe.2021.04.038","article-title":"Composite CD79A\/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival","volume":"29","author":"Julamanee","year":"2021","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0695","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/cmi.2017.161","article-title":"Functions of NKG2D in CD8(+) T cells: an opportunity for immunotherapy","volume":"15","author":"Prajapati","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0700","doi-asserted-by":"crossref","first-page":"e1509173","DOI":"10.1080\/2162402X.2018.1509173","article-title":"DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells","volume":"8","author":"Zhao","year":"2018","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0705","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/protein\/gzn055","article-title":"Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors","volume":"22","author":"Leyton","year":"2009","journal-title":"Protein Eng. Des. Sel."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.139829_bb0710","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/hum.2013.209","article-title":"A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer","volume":"25","author":"Abate-Daga","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0715","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0720","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0725","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00432-022-04017-x","article-title":"CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer","volume":"148","author":"Zhu","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.139829_bb0730","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0735","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-018-0341-1","article-title":"High-affinity CD16-polymorphism and fc-engineered antibodies enable activity of CD16-chimeric antigen receptormodified T cells for cancer therapy","volume":"120","author":"Rataj","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0740","doi-asserted-by":"crossref","first-page":"e005054","DOI":"10.1136\/jitc-2022-005054","article-title":"Chimeric antigen receptor T cells engineered to recognize the P329Gmutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors","volume":"10","author":"Stock","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0745","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0750","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1053\/j.gastro.2020.02.011","article-title":"Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice","volume":"158","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0755","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-22-0073","article-title":"Development of highly effective anti-mesothelin hYP218 chimeric antigen receptor T cells with increased tumor infiltration and persistence for treating solid tumors","volume":"21","author":"Tomar","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0760","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0765","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0770","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.32279","article-title":"Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma","volume":"76","author":"Caraballo Galva","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0775","article-title":"Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies","volume":"21","author":"Tsiverioti","year":"2024","journal-title":"Biol. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb0780","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/mi.2015.69","article-title":"CD161intCD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut","volume":"9","author":"Fergusson","year":"2016","journal-title":"Mucosal Immunol."},{"issue":"592","key":"10.1016\/j.ijbiomac.2025.139829_bb0785","doi-asserted-by":"crossref","first-page":"eabc3196","DOI":"10.1126\/scitranslmed.abc3196","article-title":"A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma","volume":"13","author":"Konduri","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0790","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CARmacrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb0795","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ccell.2021.07.009","article-title":"Tumor heterogeneity","volume":"39","author":"Pe\u2019er","year":"2021","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0800","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41568-019-0185-x","article-title":"An analysis of genetic heterogeneity in untreated cancers","volume":"19","author":"Reiter","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0805","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb0810","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3390\/ijms25052631","article-title":"Chimeric antigen receptor T cell therapy for hepatocellular carcinoma: where do we stand?","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0815","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/cells13010101","article-title":"Chimeric antigen receptor T cell therapy for pancreatic cancer: a review of current evidence","volume":"13","author":"Czaplicka","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0820","first-page":"2","article-title":"CAR-T cell therapy in pancreatic and biliary tract cancers: an updated review of clinical trials","author":"Drougkas","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0825","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/glycob\/cwy008","article-title":"Glycan-directed CAR-T cells","volume":"28","author":"Steentoft","year":"2018","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0830","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/cjp2.176","article-title":"An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours","volume":"6","author":"Robinson","year":"2020","journal-title":"J. Pathol. Clin. Res."},{"issue":"19","key":"10.1016\/j.ijbiomac.2025.139829_bb0835","doi-asserted-by":"crossref","first-page":"e138808","DOI":"10.1172\/jci.insight.138808","article-title":"CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth","volume":"5","author":"Zhuang","year":"2020","journal-title":"JCI Insight"},{"issue":"38","key":"10.1016\/j.ijbiomac.2025.139829_bb0840","doi-asserted-by":"crossref","first-page":"13939","DOI":"10.1074\/jbc.RA119.009091","article-title":"Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP\/TAZ protein signaling","volume":"294","author":"Gopal","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0845","doi-asserted-by":"crossref","first-page":"101803","DOI":"10.1016\/j.tranon.2023.101803","article-title":"Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models","volume":"39","author":"Yuan","year":"2024","journal-title":"Transl. Oncol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.139829_bb0850","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0855","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-018-0769-1","article-title":"Targeting Gas6\/TAM in cancer cells and tumor microenvironment","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0860","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen Ror1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0865","doi-asserted-by":"crossref","first-page":"e008261","DOI":"10.1136\/jitc-2023-008261","article-title":"Armored TGF\u03b2RIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGF\u03b21","volume":"12","author":"Tran","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0870","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/cancers11010051","article-title":"Endothelial protein C receptor (EPCR), protease activated receptor-1 (PAR-1) and their interplay in cancer growth and metastatic dissemination","volume":"11","author":"Wojtukiewicz","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0875","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12916-023-03053-9","article-title":"Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer","volume":"21","author":"Hung","year":"2023","journal-title":"BMC Med."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0880","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41551-022-00875-5","article-title":"CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers","volume":"6","author":"Jin","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0885","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.immuni.2018.03.028","article-title":"The transcription factor Runx3 establishes chromatin accessibility of cis-regulatory landscapes that drive memory cytotoxic T lymphocyte formation","volume":"48","author":"Wang","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0890","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2022.12.009","article-title":"Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0895","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jb\/mvq034","article-title":"Dlk-1, a cell surface antigen on foetal hepatic stem\/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency","volume":"148","author":"Yanai","year":"2010","journal-title":"J. Biochem."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb0900","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/liv.15411","article-title":"DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma","volume":"42","author":"Zhai","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0905","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0910","article-title":"Novel CAR-T cells targeting TRKB for the treatment of solid cancer","volume":"18","author":"Liang","year":"2024","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0915","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7555\/JBR.35.20200207","article-title":"c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo","volume":"36","author":"Huang","year":"2021","journal-title":"J. Biomed. Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0920","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1186\/s12967-023-04521-9","article-title":"Tyrosine kinase signaling-independent MET-targeting with CAR-T cells","volume":"21","author":"Qin","year":"2023","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb0925","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-12-2791","article-title":"Targeting the HGF\/c-MET pathway in hepatocellular carcinoma","volume":"19","author":"Goyal","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb0930","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/08820139.2023.2232402","article-title":"HGF-based CAR-T cells target hepatocellular carcinoma cells that express high levels of c-Met","volume":"52","author":"Ma","year":"2023","journal-title":"Immunol. Investig."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0935","doi-asserted-by":"crossref","first-page":"153022","DOI":"10.1016\/j.prp.2020.153022","article-title":"Integrin \u03b1v\u03b26 predicts poor prognosis and promotes resistance to cisplatin in hilar cholangiocarcinoma","volume":"216","author":"Sun","year":"2020","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0940","doi-asserted-by":"crossref","first-page":"657868","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin \u03b1v\u03b26 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0945","doi-asserted-by":"crossref","first-page":"9","DOI":"10.12688\/wellcomeopenres.10646.1","article-title":"Revisiting olfactory receptors as putative drivers of cancer","volume":"2","author":"Ranzani","year":"2017","journal-title":"Wellcome Open Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0950","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1158\/1535-7163.MCT-21-0872","article-title":"Olfactory receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors","volume":"21","author":"Martin","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0955","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-016-1949-8","article-title":"Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0960","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CJI.0000000000000349","article-title":"Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma","volume":"44","author":"Yu","year":"2021","journal-title":"J. Immunother."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb0965","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/15384047.2020.1743158","article-title":"A novel targeted GPC3\/CD3 bispecific antibody for the treatment hepatocellular carcinoma","volume":"21","author":"Yu","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb0970","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRP\u03b1-CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb0975","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0980","first-page":"156","article-title":"Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy","volume":"13","author":"Li","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb0985","first-page":"101324","article-title":"GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay","volume":"31","author":"Cao","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.139829_bb0990","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb0995","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-018-0646-9","article-title":"Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1000","doi-asserted-by":"crossref","first-page":"863346","DOI":"10.3389\/fimmu.2022.863346","article-title":"Orthotopic and heterotopic murine models of pancreatic cancer exhibit different immunological microenvironments and different responses to immunotherapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb1005","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.ymthe.2020.07.017","article-title":"Dual targeting of mesothelin and CD19 with chimeric antigen receptor-modified T cells in patients with metastatic pancreatic cancer","volume":"28","author":"Ko","year":"2020","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1010","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1015","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-018-0591-7","article-title":"Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1025","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1030","doi-asserted-by":"crossref","first-page":"e001875","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in hepatocellular carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1035","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s42003-020-01464-5","article-title":"Multiple proteases are involved in mesothelin shedding by cancer cells","volume":"3","author":"Liu","year":"2020","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcyt.2024.01.011","article-title":"Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity","volume":"26","author":"Chu","year":"2024","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317283121","article-title":"Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope","volume":"121","author":"Liu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1050","doi-asserted-by":"crossref","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","article-title":"Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1055","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.139829_bb1060","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00262-018-2221-1","article-title":"Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein","volume":"67","author":"Pan","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb1065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omto.2021.03.014","article-title":"Secretion of bispecific protein of antiPD-1 fused with TGF-\u03b2 trap enhances antitumor efficacy of CAR-T cell therapy","volume":"21","author":"Chen","year":"2021","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1075","doi-asserted-by":"crossref","first-page":"546586","DOI":"10.3389\/fonc.2021.546586","article-title":"Bispecific c-Met\/PD-L1 CAR-T cells have enhanced therapeutic effects on hepatocellular carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/ijo.2023.5501","article-title":"Bispecific GPC3\/PD-1 CAR-T cells for the treatment of HCC","volume":"62","author":"Li","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb1085","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb1090","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"issue":"3\u20134","key":"10.1016\/j.ijbiomac.2025.139829_bb1095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","article-title":"Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor","volume":"51","author":"Prosser","year":"2012","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcyt.2022.10.006","article-title":"Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells","volume":"25","author":"Supimon","year":"2023","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrg2703","article-title":"Origin and evolution ofthe adaptive immune system: genetic events and selective pressures","volume":"11","author":"Flajnik","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1110","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.omto.2022.02.015","article-title":"A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer","volume":"24","author":"Li","year":"2022","journal-title":"Mol. Ther. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1115","doi-asserted-by":"crossref","first-page":"19712","DOI":"10.1038\/s41598-021-99311-y","article-title":"Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment","volume":"11","author":"Oh","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2019.01.016","article-title":"High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells","volume":"447","author":"Liang","year":"2019","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1125","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/imm.13624","article-title":"Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma","volume":"169","author":"Chen","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2017.00248","article-title":"Metabolic hallmarks of tumor and immune cells in the tumor microenvironment","volume":"8","author":"Renner","year":"2017","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb1135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.it.2018.01.005","article-title":"Reactive oxygen species: involvement in T cell signaling and metabolism","volume":"39","author":"Franchina","year":"2018","journal-title":"Trends Immunol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.139829_bb1140","doi-asserted-by":"crossref","first-page":"e002755","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy","volume":"9","author":"He","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4049\/jimmunol.1401710","article-title":"Co-expressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb1150","doi-asserted-by":"crossref","first-page":"e004458","DOI":"10.1136\/jitc-2021-004458","article-title":"Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress","volume":"10","author":"Renken","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1155","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajhg.2019.07.015","article-title":"Bi-allelic GOT2 mutations cause a treatable malate-aspartate shuttle-related encephalopathy","volume":"105","author":"van Karnebeek","year":"2019","journal-title":"Am. J. Hum. Genet. Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb1160","doi-asserted-by":"crossref","first-page":"e0266980","DOI":"10.1371\/journal.pone.0266980","article-title":"BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity","volume":"17","author":"Hickman","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2024.02.003","article-title":"From suppressor to enhancer: IL-10\u2019s alternative role in CAR-T cell therapies against solid tumors","volume":"31","author":"Huang","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1175","doi-asserted-by":"crossref","first-page":"116052","DOI":"10.1016\/j.biopha.2023.116052","article-title":"Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model","volume":"170","author":"Takeuchi","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/CJI.0000000000000207","article-title":"Cholesterol esterification enzyme inhibition enhances antitumor effects of human chimeric antigen receptors modified T cells","volume":"41","author":"Zhao","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1185","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omto.2020.01.008","article-title":"Inhibition of cholesterol esterification enzyme enhances the potency of human chimeric antigen receptor T cells against pancreatic carcinoma","volume":"16","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb1190","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1195","doi-asserted-by":"crossref","first-page":"1209572","DOI":"10.3389\/fimmu.2023.1209572","article-title":"PGE2-EP2\/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer","volume":"14","author":"Akbari","year":"2023","journal-title":"Front. Immunol."},{"issue":"628","key":"10.1016\/j.ijbiomac.2025.139829_bb1200","doi-asserted-by":"crossref","first-page":"eabg3072","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: from basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1210","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.139829_bb1215","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ymthe.2019.04.020","article-title":"Combined antitumor effects of Sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma","volume":"27","author":"Wu","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1220","doi-asserted-by":"crossref","first-page":"963031","DOI":"10.3389\/fimmu.2022.963031","article-title":"Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-cells plus sorafenib, a case report","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb1225","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the antitumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1230","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb1235","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41419-023-05883-0","article-title":"TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1\/eEF1A1 signal pathway","volume":"14","author":"Wu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb1240","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/2326-6066.CIR-23-0587","article-title":"The TOPK inhibitor HI-TOPK-032 enhances CAR T-cell therapy of hepatocellular carcinoma by upregulating memory T cells","volume":"12","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.139829_bb1245","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-21-1141","article-title":"A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer","volume":"27","author":"Ali","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.139829_bb1250","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/cells8091070","article-title":"Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma","volume":"8","author":"Yazdanifar","year":"2019","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb1255","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ng.392","article-title":"Lin28 promotes transformation and is associated with advanced human malignancies","volume":"41","author":"Viswanathan","year":"2009","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1260","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ymthe.2023.01.002","article-title":"Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population","volume":"31","author":"Patra","year":"2023","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1265","doi-asserted-by":"crossref","first-page":"e006119","DOI":"10.1136\/jitc-2022-006119","article-title":"Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability","volume":"11","author":"Tang","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1270","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3 specific antibody drug conjugates targeting hepatocellular carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb1275","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ymthe.2021.02.004","article-title":"Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity","volume":"29","author":"McKenna","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1280","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front. Immunol."},{"issue":"28","key":"10.1016\/j.ijbiomac.2025.139829_bb1285","doi-asserted-by":"crossref","first-page":"e2212210","DOI":"10.1002\/adma.202212210","article-title":"Inhibition of tumor metastasis by liquid-nitrogen-shocked tumor cells with oncolytic viruses infection","volume":"35","author":"Wu","year":"2023","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1290","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41420-023-01626-4","article-title":"Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-\u03b3 promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors","volume":"9","author":"Fang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.139829_bb1295","doi-asserted-by":"crossref","first-page":"e99573","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"issue":"559","key":"10.1016\/j.ijbiomac.2025.139829_bb1300","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1305","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/XCS.0000000000000964","article-title":"Using oncolytic virus to retask CD19-chimeric antigen receptor-T cells for treatment of pancreatic cancer: toward a universal chimeric antigen receptor-T cell strategy for solid tumors","volume":"238","author":"Chen","year":"2024","journal-title":"J. Am. Coll. Surg."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1310","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s42003-021-01914-8","article-title":"Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors","volume":"4","author":"Rosewell Shaw","year":"2021","journal-title":"Commun. Biol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.139829_bb1315","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb1320","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ymthe.2021.02.004","article-title":"Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity","volume":"29","author":"McKenna","year":"2021","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.139829_bb1325","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CAR T-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1330","doi-asserted-by":"crossref","first-page":"121138","DOI":"10.1016\/j.biomaterials.2021.121138","article-title":"Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma","volume":"278","author":"Kumar","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1335","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1021\/acs.biomac.5b01419","article-title":"EGFR-targeted polymeric mixed micelles carrying gemcitabine for treating pancreatic cancer","volume":"17","author":"Mondal","year":"2016","journal-title":"Biomacromolecules"},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.139829_bb1340","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.7150\/thno.24945","article-title":"Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice","volume":"8","author":"Kumar","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1345","doi-asserted-by":"crossref","first-page":"1604300","DOI":"10.1002\/adfm.201604300","article-title":"Cancer cell membrane-coated gold nanocages with hyperthermia-triggered drug release and homotypic target inhibit growth and metastasis of breast cancer","volume":"27","author":"Sun","year":"2017","journal-title":"Adv. Funct. Mater."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1350","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12967-024-05159-x","article-title":"Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology","volume":"22","author":"Lin","year":"2024","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1355","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00262-023-03602-4","article-title":"New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo","volume":"73","author":"Jancewicz","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1360","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.139829_bb1365","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-18-0306","article-title":"Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1370","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1375","doi-asserted-by":"crossref","first-page":"e75660","DOI":"10.7554\/eLife.75660","article-title":"De novo-designed transmembrane domains tune engineered receptor functions","volume":"11","author":"Elazar","year":"2022","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1380","doi-asserted-by":"crossref","first-page":"e0022","DOI":"10.1097\/HC9.0000000000000022","article-title":"Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC","volume":"7","author":"Kolluri","year":"2023","journal-title":"Hepatol. Commun."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.139829_bb1385","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nano-body-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1390","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41467-023-37616-4","article-title":"The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.139829_bb1395","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1021\/acs.nanolett.3c00071","article-title":"An Fc binding peptide-based facile and versatile build platform for multispecific antibodies","volume":"23","author":"Xue","year":"2023","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41551-021-00772-3","article-title":"Enhancing the tropism of bacteria via genetically programmed biosensors","volume":"6","author":"Chien","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"6667","key":"10.1016\/j.ijbiomac.2025.139829_bb1405","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.add7034","article-title":"Probiotic-guided CAR-T cells for solid tumor targeting","volume":"382","author":"Vincent","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1410","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12967-020-02462-1","article-title":"32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma","volume":"18","author":"Liu","year":"2020","journal-title":"J. Transl. Med."},{"issue":"23","key":"10.1016\/j.ijbiomac.2025.139829_bb1415","doi-asserted-by":"crossref","first-page":"e1900192","DOI":"10.1002\/adma.201900192","article-title":"Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1420","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/thno.40291","article-title":"Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1425","doi-asserted-by":"crossref","first-page":"nwab172","DOI":"10.1093\/nsr\/nwab172","article-title":"Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy","volume":"9","author":"Li","year":"2021","journal-title":"Natl. Sci. Rev."},{"issue":"42","key":"10.1016\/j.ijbiomac.2025.139829_bb1430","doi-asserted-by":"crossref","first-page":"44179","DOI":"10.18632\/oncotarget.6175","article-title":"Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1435","doi-asserted-by":"crossref","first-page":"nwae018","DOI":"10.1093\/nsr\/nwae018","article-title":"Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor","volume":"11","author":"Liao","year":"2024","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1440","article-title":"Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors","author":"Johnston","year":"2024","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1445","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1038\/s41467-023-41282-x","article-title":"Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.139829_bb1450","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/cancers15061808","article-title":"Adoptive cell therapy in hepatocellular carcinoma: a review of clinical trials","volume":"15","author":"Ozer","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.139829_bb1455","first-page":"00027","article-title":"The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer","volume":"S2090-1232","author":"Tang","year":"2024","journal-title":"J. Adv. Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12029-020-00457-1","article-title":"CAR T cell therapy in pancreaticobiliary cancers: a focused review of clinical data","volume":"52","author":"Anwar","year":"2021","journal-title":"J. Gastrointest. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1465","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s12029-024-01054-2","article-title":"CAR-T cell therapy in pancreatic and biliary tract cancers: an updated review of clinical trials","volume":"55","author":"Drougkas","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1470","doi-asserted-by":"crossref","first-page":"1369352","DOI":"10.3389\/fphar.2024.1369352","article-title":"Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2430302","article-title":"Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis","volume":"4","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1480","doi-asserted-by":"crossref","first-page":"151850","DOI":"10.1016\/j.imbio.2019.09.009","article-title":"PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma","volume":"225","author":"Wang","year":"2020","journal-title":"Immunobiology"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.139829_bb1485","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.7150\/ijms.45603","article-title":"EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma","volume":"17","author":"Ma","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1490","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cellimm.2018.04.007","article-title":"Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer","volume":"329","author":"He","year":"2018","journal-title":"Cell. Immunol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.139829_bb1495","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317695949","article-title":"Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma","volume":"39","author":"Xu","year":"2017","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1500","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","article-title":"Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1505","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1510","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.139829_bb1515","doi-asserted-by":"crossref","first-page":"15479","DOI":"10.3390\/ijms232415479","article-title":"The role of microRNAs in inflammation","volume":"23","author":"Das","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.139829_bb1520","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/all.15111","article-title":"Regulatory roles of three miRNAs on allergen mRNA expression in Tyrophagus putrescentiae","volume":"77","author":"Zhou","year":"2022","journal-title":"Allergy"},{"issue":"Pt B","key":"10.1016\/j.ijbiomac.2025.139829_bb1525","doi-asserted-by":"crossref","first-page":"110974","DOI":"10.1016\/j.intimp.2023.110974","article-title":"IL-7 promotes CD19-directed CAR-T cells proliferation through miRNA-98-5p by targeting CDKN1A","volume":"124","author":"Yang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1530","doi-asserted-by":"crossref","first-page":"811364","DOI":"10.3389\/fimmu.2021.811364","article-title":"Co-expression of miR155 or LSD1 shRNA increases the anti-tumor functions of CD19 CAR-T cells","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.139829_bb1535","doi-asserted-by":"crossref","first-page":"100978","DOI":"10.1016\/j.xcrm.2023.100978","article-title":"mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy","volume":"4","author":"Olivera","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.139829_bb1540","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-018-0600-x","article-title":"miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy","volume":"11","author":"Huang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.139829_bb1545","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2051-1426-1-21","article-title":"Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts","volume":"1","author":"Ohno","year":"2013","journal-title":"J. Immunother. Cancer"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025003782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025003782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:00:05Z","timestamp":1782756005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025003782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":309,"alternative-id":["S0141813025003782"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.139829","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.139829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"139829"}}